Clinical trials: High Altitude Pulmonary Hypertension
Pulmonary Vascular Disease, Pulmonary Artery Hypertension
HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)
To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH)…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT05996302
- Testing
- Relocation to sea level
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
Cerebral Tissue Oxygenation in Highlanders/Lowlanders
The purpose of the current study is to evaluate the cerebral tissue oxygenation of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study.
- Trial name
- NCT03172429
- Where
- Kyrgyzstan
- Volunteers
- 79 people
- Sponsor
- University of Zurich
High Altitude Polycythemia
Treatment of High Altitude Polycythemia by Acetazolamide
The prevalence of High Altitude Polycythemia (or Chronic Mountain Sickness) is between 8 and 15% in the high altitude regions of South America. There is no pharmacological treatment available.
- Trial name
- NCT00424970
- Testing
- acetazolamide
- Where
- Peru
- Volunteers
- 55 people
- Sponsor
- Association pour la Recherche en Physiologie de l'Environnement
High Altitude Pulmonary Hypertension
Right Ventricular Function at Rest in Highlanders/Lowlanders
The purpose of the current study is to evaluate the progression of right ventricular function and dimension in Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a cross sectional case-control study.
- Trial name
- NCT03165656
- Where
- Kyrgyzstan
- Volunteers
- 173 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)
To study the effect of relocation from 3200 m (Aksay) to 760 m (Bishkek) in patients with high altitude pulmonary hypertension (HAPH) who permanently live >2500 m on pulmonary artery pressure (PAP)
- Trial name
- NCT06489704
- Testing
- Echocardiography
- Where
- Kyrgyzstan
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Total Pulmonary Resistance sPAP/CO Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in patients with…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, High Altitude, Echocardiography
- Trial name
- NCT07804693
- Testing
- Re-Ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Hypertension
Acute Exposure to High Altitude on Heart Rate and Ventilation During Exercise
Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (Säntis; 2500m above sea level) on heart rate and Ventilation changes under exercise.
- Trial name
- NCT03593096
- Testing
- Assessment at Low Altitude (470m above sea level), Exposure to High Altitude (2500m above sea level)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Six-minute Walking Distance 6MWD Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of relocation from high altitude (Quito: 2850m) to sea level on six-minute walking distance and scores in patients with pulmonary arterial hypertension PAH, who live permanently >2600m.
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, Six-minute Walk Test, High Altitude Effects
- Trial name
- NCT07804472
- Testing
- Descent from 2850m to sea level
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Hypertension
Acute Exposure of High Altitude on Cognitive Function
Randomized crossover Trial in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary Hypertension (CTEPH) to assess the acute response to High Altitude (2500m above sea level) on cognitive…
- Trial name
- NCT03637192
- Testing
- Low altitude: 470m above sea level, Säntis; 2500m above sea Level
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
High Altitude, Healthy
Assessment of Six-minute Walking Distance Between Sea Level LA vs. High Altitude HA After Re-ascent in Healthy Individuals
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on six-minute walking distance and other scores in healthy individuals, who live…
- Conditions
- High Altitude, Healthy, Healthy Adult, Six-minute Walk Test
- Trial name
- NCT07797088
- Testing
- Re-Ascent sea level to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
High Altitude Pulmonary Hypertension, Sleep Apnea
HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.
The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study.
- Trial name
- NCT06489730
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Hypoxia-Induced Pulmonary Artery Hypertension
Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia
Excessive rise in pulmonary artery pressure induced by low oxygen tension (hypoxia) is one of the factors implicated in high-altitude pulmonary oedema.
- Trial name
- NCT00260819
- Testing
- Bosentan, Bosentam TRACLEER
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
High Altitude Pulmonary Hypertension, Sleep Apnea
Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.
The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study.
- Trial name
- NCT03165019
- Where
- Kyrgyzstan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Pulmonary Hypertension
Acute Excposure of High Altitude on ECG and Non-invasive Blood Pressure.
Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response of High Altitude (Säntis, 2500m above sea level) on ECG repolarizations and non-invasive blood pressure measurements by…
- Trial name
- NCT03593083
- Testing
- Low altitude: 470m above sea level, Säntis; 2500m above sea Level
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension, Sleep Apnea
Sleep Related Breathing Disturbances and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders
High altitude pulmonary hypertension, a form of altitude illness that occurs in long-term residents at altitudes >2500 m, is characterized by dyspnea, hypoxemia, impaired exercise performance and hypertension in the pulmonary…
- Trial name
- NCT01621061
- Where
- Kyrgyzstan
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- University of Zurich